Literature DB >> 19586962

Is there a role of the histologic subtypes of papillary renal cell carcinoma as a prognostic factor?

Ja Hyeon Ku1, Kyung Chul Moon, Cheol Kwak, Hyeon Hoe Kim, Sang Eun Lee.   

Abstract

OBJECTIVE: The aim of this study was to compare type 1 and type 2 papillary renal cell carcinoma (RCC) for validating this subclassification as a prognostic factor.
METHODS: A total of 70 patients with chromophobe RCC were included in the analysis. Patients with papillary RCC were categorized into type 1 (n = 33) and type 2 (n = 37).
RESULTS: The median progression-free survival was 31.0 months for the type 1 group and 12.0 months for the type 2 group (P = 0.001). The median cancer-specific survival was 41.1 months for the type 1 group and 24.0 months for the type 2 group (P = 0.097). Multivariate Cox proportional hazards model for patients with papillary RCC showed that no variables including histologic subtyping were independent predictors of progression-free and cancer-specific survival.
CONCLUSIONS: In the present study, the type of papillary RCC does not reach independent prognostic significance.

Entities:  

Mesh:

Year:  2009        PMID: 19586962     DOI: 10.1093/jjco/hyp075

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  8 in total

1.  [Clinicopathological features and prognostic analysis of papillary renal cell carcinoma].

Authors:  E S Bo; P Hong; Y Zhang; S H Deng; L Y Ge; M Lu; N Li; L L Ma; S D Zhang
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2022-08-18

2.  Prognostic implications of the magnetic resonance imaging appearance in papillary renal cell carcinoma.

Authors:  Andrew B Rosenkrantz; Aarti Sekhar; Elizabeth M Genega; Jonathan Melamed; James S Babb; Amish D Patel; Andy Lo; Robert M Najarian; Muneeb Ahmed; Ivan Pedrosa
Journal:  Eur Radiol       Date:  2012-08-21       Impact factor: 5.315

3.  Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery.

Authors:  Rodrigo A Ledezma; Edris Negron; Gladell P Paner; Chris Rjepaj; Danny Lascano; Mohammed Haseebuddin; Pankaj Dangle; Arieh L Shalhav; Henry Crist; Jay D Raman; G Joel DeCastro; Lara Harik; Monika Paroder; Robert G Uzzo; Alexander Kutikov; Scott E Eggener
Journal:  World J Urol       Date:  2015-09-25       Impact factor: 4.226

Review 4.  Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer.

Authors:  Theodore F Logan
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

Review 5.  MRI phenotype in renal cancer: is it clinically relevant?

Authors:  Naomi Campbell; Andrew B Rosenkrantz; Ivan Pedrosa
Journal:  Top Magn Reson Imaging       Date:  2014-04

6.  Identification of topological features in renal tumor microenvironment associated with patient survival.

Authors:  Jun Cheng; Xiaokui Mo; Xusheng Wang; Anil Parwani; Qianjin Feng; Kun Huang
Journal:  Bioinformatics       Date:  2018-03-15       Impact factor: 6.937

7.  Clinicopathological Features and Prognostic Outcomes of Papillary Renal Cell Carcinoma.

Authors:  Xiaoyuan Qian; Junlai Wan; Can Qian; Jiaqiao Zhang
Journal:  Int J Gen Med       Date:  2021-11-02

8.  Whether histologic subtyping affect the oncological outcomes of patients with papillary renal cell carcinoma: evidence from a systematic review and meta-analysis.

Authors:  Shengwei Xiong; Weijie Zhu; Xinfei Li; Yanfei Yu; Kunlin Yang; Lei Zhang; Yue Mi; Xuesong Li; Liqun Zhou
Journal:  Transl Androl Urol       Date:  2021-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.